{'fraction_non_alphanumeric': 0.020454545454545454, 'fraction_numerical': 0.0, 'mean_word_length': 5.430656934306569, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Molecular insights into the development of T cell-based immunotherapy for prostate cancer

Using a patient’s own immune system to fight cancer is a highly active area of cancer research. Four years ago, sipuleucel-T became the first approved cancer vaccine, which was developed to enhance T-cell immunity against metastatic castration-resistant prostate cancer. Other prostate cancer vaccines, including a viral-based vaccine PROSTVAC-VF and a cellular vaccine GVAX, are in development. Moreover, several clinical trials are investigating the role of immune checkpoint blockade in the treatment of prostate cancer. Ipilimumab and nivolumab are potent T cell checkpoint inhibitors that reverse immunologic tolerance in multiple types of cancers. Here we discuss the mechanisms underlying antitumor T cell responses as well as the development of immunotherapies for prostate cancer.